CTS™ AIM V™ SFM

Citas y referencias (27)

Gibco™

CTS™ AIM V™ SFM

Name: CTS™ AIM V™ SFM
SKU: 0870112BK

SFM CTS AIM V Gibco (calidad terapéutica) es el primer medio sin suero (SFM) disponible comercialmente para la el proliferaciónMás información

Cambiar vista

Número de catálogo	Cantidad
0870112BK	10 L
0870112DK	1000 mL

2 opciones

Número de catálogo 0870112BK

Precio (MXN)

Cantidad:

10 L

SFM CTS AIM V Gibco (calidad terapéutica) es el primer medio sin suero (SFM) disponible comercialmente para la el proliferación y/o manipulación de células T y células dendríticas, y fabricado según las buenas prácticas de fabricación actuales. Contiene L-glutamina, sulfato de estreptomicina a 50 µg/ml y sulfato de gentamicina a 10 µg/m.

Diseñado para aplicaciones de procesamiento de cultivos celulares y de tejido ex vivo.PRECAUCIÓN:Cuando se utiliza como dispositivo médico, la ley federal restringe su venta a los médicos o por orden de estos.

Especificaciones

Tipo de célulaMonocitos, células dendríticas, células T, hibridomas, PBMC, fibroblastos, macrófagos, células de mieloma, linfocitos

Para utilizar con (aplicación)Investigación de terapias con células

FormatoBolsa universal

Calidad de fabricaciónISO 13485, MDSAP, FDA-registered, 21 CFR 820

Tipo de productoMedio sin suero (SFM)

Cantidad10 L

Duración de almacenamiento14 meses

Condiciones de envíoAmbiente

ClasificaciónSin suero

FormularioLíquido

Serum LevelSin suero

EsterilidadEstéril con filtro

Unit SizeEach

Contenido y almacenamiento

Almacenar el medio entre 2 y 8°C. Proteja el producto de la luz. AIM V™ tiene una vida útil de 14 meses.

Preguntas frecuentes

Will CTS AIM V SFM (Cat. No. 0870112BK) be discontinued?

No. CTS AIM V SFM (Cat. No. 0870112BK) will not be discontinued. The same catalog number will be available with the new Aegis5-14 film following the planned transition in 2026.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Where can I get more information about Aegis 5-14 BPC (BioProcessing Container)?

For additional information regarding Aegis 5-14 BPC, reach out to our Cell Culture Technical Support Team at techsupport@thermofisher.com.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

What type of film is currently used for packaging CTS AIM V SFM (Cat. No. 0870112BK)?

CTS AIM V SFM (Cat. No. 0870112BK) is packaged in ASI 28 film, featuring an ethylene vinyl acetate (EVA) contact layer and four spike ports.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

What is the difference between CTS AIM V SFM VALIDATION (Cat. No. A4000311302) and CTS AIM V SFM (Cat. No. 0870112BK)?

The two media have the same formulation and GMP quality and are manufactured in ISO13485, MDSAP, FDA-registered, 21 CFR820 facilities. The main difference lies in the packaging. CTS AIM V SFM VALIDATION (Cat. No. A4000311302) is packaged in the Aegis 5-14 BioProcessing Container (BPC) with a low-density polyethylene (LDPE) contact layer and updated tubing and connector options. On the other hand, the current CTS AIM V SFM (Cat. No. 0870112BK) is packaged in ASI 28 film with an ethylene vinyl acetate (EVA) contact layer and four spike ports.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

What is CTS?

The Gibco Cell Therapy Systems (CTS) portfolio of cell and gene therapy products are GMP manufactured, safety tested, and backed by regulatory documentation to support your transition from discovery through clinical and commercial manufacturing. Through our CTS solutions, we are committed to helping customers streamline therapeutic development, minimize risk, and ease the burden on their quality systems. Learn more here.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

View all CTS™ AIM V™ SFM FAQs

Citations & References (27)

Citations & References

Abstract

Live attenuated lentivirus infection elicits polyfunctional simian immunodeficiency virus Gag-specific CD8+ T cells with reduced apoptotic susceptibility in rhesus macaques that control virus replication after challenge with pathogenic SIVmac239.

Authors:Genescà M, Rourke T, Li J, Bost K, Chohan B, McChesney MB, Miller CJ,

Journal:J Immunol

PubMed ID:17878372

'HIV-specific CD8+ T cells that secrete multiple cytokines in response to Ag stimulation are associated with the control of virus replication during chronic HIV infection. To determine whether the presence of polyfunctional CD8+ T cell responses distinguishes protected and unprotected monkeys in a live attenuated lentivirus model, SIV Gag peptide-specific ... More

Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.

Authors:Janetzki S, Price L, Britten CM, van der Burg SH, Caterini J, Currier JR, Ferrari G, Gouttefangeas C, Hayes P, Kaempgen E, Lennerz V, Nihlmark K, Souza V, Hoos A,

Journal:Cancer Immunol Immunother

PubMed ID:19894047

'The choice of serum for supplementation of media for T cell assays and in particular, Elispot has been a major challenge for assay performance, standardization, optimization, and reproducibility. The Assay Working Group of the Cancer Vaccine Consortium (CVC-CRI) has recently identified the choice of serum to be the leading cause ... More

[Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation]

Authors:Nomura K, Fujioka T,

Journal:Nippon Hinyokika Gakkai Zasshi

PubMed ID:8320888

'We evaluated adoptive immunotherapy using LAK cells combined with systemic administration of interleukin-2 (IL-2) in 11 patients with metastatic renal cell carcinoma. The LAK cells were generated by incubation in serum-free medium (AIM-V) supplemented with IL-2 (1,000 U/ml) for 4 days and were generally administered twice weekly (4 times/cycle). Daily ... More

Abnormal acidification of melanoma cells induces tyrosinase retention in the early secretory pathway.

Authors: Halaban Ruth; Patton Robin S; Cheng Elaine; Svedine Sherri; Trombetta E Sergio; Wahl Miriam L; Ariyan Stephen; Hebert Daniel N;

Journal:J Biol Chem

PubMed ID:11812790

'In tyrosinase-positive amelanotic melanoma cells, inactive tyrosinase accumulates in the endoplasmic reticulum. Based on studies described here, we propose that aberrant vacuolar proton ATPase (V-ATPase)-mediated proton transport in melanoma cells disrupts tyrosinase trafficking through the secretory pathway. Amelanotic but not melanotic melanoma cells or normal melanocytes display elevated proton export ... More

Serum-free culture medium and IL-7 costimulation increase the sensitivity of ELISpot detection.

Authors:Martinuzzi E, Scotto M, Enée E, Brezar V, Ribeil JA, van Endert P, Mallone R

Journal:J Immunol Methods

PubMed ID:18242633

'The identification of parameters maximizing detection sensitivity in ELISpot assays is important to transfer this technology into the clinical setting for identifying rare Ag-specific CD8(+) T cells. We have therefore considered human IFN-gamma CD8(+) T cell responses against viral epitopes to analyze different variables which could be critical during the ... More

View all CTS™ AIM V™ SFM citations